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Introduction: CT-guided, frameless radiosurgery is an alternative treatment to traditional
catheter-angiography targeted, frame-based methods for intracranial arteriovenous mal-
formations (AVMs). Despite the widespread use of frameless radiosurgery for treating
intracranial tumors, its use for treating AVM is not-well described.
Methods: Patients who completed a course of single fraction radiosurgery at The Univer-
sity of North Carolina or Georgetown University between 4/1/2005–4/1/2011 with single
fraction radiosurgery and received at least one follow-up imaging study were included.
All patients received pre-treatment planning with CTA±MRA and were treated on the
CyberKnife (Accuray) radiosurgery system. Patients were evaluated for changes in clinical
symptoms and radiographic changes evaluated with MRI/MRA and catheter-angiography.
Results: Twenty-six patients, 15 male and 11 female, were included in the present study
at a median age of 41 years old. The Spetzler-Martin grades of the AVMs included seven
Grade I, 12 Grade II, six Grade III, and one Grade IV with 14 (54%) of the patients having a
pre-treatment hemorrhage. Median AVM nidal volume was 1.62 cm3 (0.57–8.26 cm3) and
was treated with a median dose of 1900 cGy to the 80% isodose line. At median follow-up
of 25 months, 15 patients had a complete closure of their AVM, 6 patients had a partial
closure, and 5 patients were stable. Time since treatment was a significant predictor of
response, with patients experience complete closure having on average 11 months more
follow-up than patients with partial or no closure (p=0.03). One patient experienced a
post-treatment hemorrhage at 22 months.
Conclusion: Frameless radiosurgery can be targeted with non-invasive MRI/MRA and
CTA imaging. Despite the difficulty of treating AVM without catheter angiography, early
results with frameless, CT-guided radiosurgery suggest that it can achieve similar results
to frame-based methods at these time points.
Keywords: stereotactic radiosurgery, arteriovenous malformations, image guided radiation therapy, outcomes, CT
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INTRODUCTION
Intracranial arteriovenous malformations (AVMs) present one of
the greatest clinical challenges for neurosurgeons, radiation oncol-
ogists, and neurointerventionalists. Classically, the treatment of
these lesions involved careful patient selection followed by large,
open surgical procedures, or more recently endovascular oblitera-
tion, radiosurgery, or a combination of these methods (1–3). This
trend of utilizing increasingly less invasive options, endovascular,
and radiosurgical, has lead to the advent of frameless radio-
surgical devices that do not require the traditional head frame
for stereotaxic guidance (4, 5). Despite the widespread adoption
of these devices for treating both intracranial and extracranial
pathologies, to the author’s knowledge to date there has been
only two reports on the results of frameless radiosurgical devices
for the treatment of intracranial AVM (5, 6). We report the
retrospective results of two institutions with using CyberKnife
frameless stereotactic radiosurgery (SRS) for the treatment of
intracranial AVM.
METHODS
PATIENT SELECTION AND TREATMENT
We performed a retrospective review of patients with intracra-
nial AVMs treated with CyberKnife SRS from December 1st, 2005
to February 1st, 2011 at Georgetown University Hospital and
the University of North Carolina at Chapel Hill. Patients who
had undergone single fraction SRS for intracranial AVM with
or without endovascular embolization and had received at least
one follow-up imaging study were included. All patients were
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FIGURE 1 | Figure demonstrating treatment planning for a representative case. Planned treatment volume (red), 90% isodose (blue), and 50% isodose
(yellow) can be seen in three planes on pre-treatment planning CTA.
treated by an interdisciplinary team of radiation oncologists and
neurosurgeons. High resolution CTA images with or without MRA
were obtained from all patients for pre-treatment planning. A
planning target volume (PTV) and critical structures were manu-
ally delineated by the treating neurosurgeon with the PTV encom-
passing the contour of the AVM with a 1 mm margin (Figure 1).
All treatment planning was performed on pre-treatment CTA
imaging, and when available, using fused MRA/CTA imaging.
The treating isodose and prescription dose were determined by
the treating radiation oncologist in consultation with the treat-
ing neurosurgeon, and took into account the AVM nidus, overall
volume, proximity to critical structures, and previous treatment
history. Treatment plans were generated using an inverse plan-
ning method by the CyberKnife treatment software (Multiplan,
Accuray).
OUTCOMES ASSESSMENT
Patients were tracked as part of routine clinical follow-up
by the interdisciplinary team. MRA scans with or without
catheter-angiography confirmation were obtained at pre-defined
annual intervals unless acute changes in neurological status war-
ranted immediate imaging. Neurological symptoms were clinically
assessed and recorded by the treating neurosurgeons. Complete
closure was defined as total resolution of the AVM nidus and
draining veins on imaging, with partial closure being defined as a
decrease in size of the nidus with the persistence of large draining
veins.
STATISTICAL ANALYSIS
All statistical analyses were performed utilizing SPSS Statistics
v19 (IBM). Statistical analysis was performed in order to identify
pre-treatment and treatment variables that correlated with AVM
closure. The Kruskal–Wallis test, a non-parametric equivalent to
ANOVA, was utilized for comparison of continuous variables
grouped by AVM closure outcomes. For analysis of volume and
dose, Pearson Chi-square testing was employed. Alpha was set to
0.05 to yield a 95% confidence interval (CI) for all statistical tests.
Averages were all reported as the median value and interquartile
range (IQR), which is a more robust measure of dispersion than
simple range.
RESULTS
PATIENT AND TREATMENT CHARACTERISTICS
Twenty-six patients were identified as having undergone treatment
for intracranial AVM and met all criteria for inclusion in the cur-
rent study (Table 1). Fifteen (58%) of the patients were male and
11 (42%) were female. The median age at time of treatment with
radiosurgery was 41 years (IQR, 26–55 years). The AVMs had a
range of Spetzler–Martin grades with 7 Grade I, 12 Grade II, 6
Grade III, and 1 Grade IV. Ten (38%) of the patients were either
current smokers or had a history of smoking, and seven (23%)
of the patients were hypertensive. Fourteen (54%) of the patients
had a pre-treatment hemorrhage, and of the hypertensive patients,
six out of seven (86%) experienced pre-treatment hemorrhage
(p= 0.027). The median AVM nidus volume was 1.62 cm3 (IQR,
0.57–8.26 cm3). Pre-treatment embolization was performed in 11
patients (42%), with 9 patients being treated with Onyx and the
others with n-butyl cyanoacrylate (NBCA). The median isodose
was 80% (76–83%), which was treated with a median prescrip-
tion dose of 1900 cGy (IQR, 1800-2175 cGy). Seventeen (65%)
of the patients had SRS as monotherapy, while nine underwent
a combination of SRS and embolization or, in one case, surgical
resection.
AVM CLOSURE RATES
At median follow-up for the cohort of 25 months (IQR, 19-
36 months), 15 patients had a complete closure of their AVM, 6
patients had a partial closure, and 5 patients were stable (Figure 2).
Time since treatment was a significant predictor of response, fully
closed AVM had, on average, 11 months more follow-up time than
those with partial or no closure (p= 0.03) (Table 2). Nidal volume
and dose did not correlate with AVM closure rate (p= 0.63, 0.12).
Spetzler–Martin Grade did not correlate with AVM closure as well
(p= 0.26).
NEUROLOGICAL DEFICITS AND TOXICITY
One patient experienced a post-treatment hemorrhage at
22 months requiring emergent surgical decompression (Table 3).
No other significant post-treatment adverse events were reported.
The most common pre-treatment neurological symptom was
headaches (46%), which improved in most cases after treatment
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Table 1 | Summary of AVM patient characteristics.
Variable Value
Subjects, N 26
Median age, years (IQR) 41 (26–55)
Gender
Male, n (%) 15 (58)
Female, n (%) 11 (42)
Smoking status
Current/prior history, n (%) 10 (38)
Never, n (%) 12 (46)
Unknown, n (%) 4 (15)
Pre-treatment neurological symptoms
Headache, n (%) 12 (46)
Seizures, controlled/uncontrolled, n/n (%/%) 2/2 (8/8)
Motor deficits, n (%) 9 (35)
Pre-treatment hemorrhage, n (%) 14 (54)
Hypertension (%) 7 (27)
Pre-treatment hemorrhage, n (%) 6 (86)
No pre-treatment hemorrhage, n (%) 1 (14)
Spetzler martin grade
I, n (%) 7
II, n (%) 12
III, n (%) 6
IV, n (%) 1
Median Nidus volume, cm3 (IQR) 1.62 (0.57–8.26)
Intervention
SRS only, n (%) 17 (65)
SRS + embolization or surgery, n (%) 9 (35)
Isodose, median % (IQR) 80 (76–83%)
Dose, median cGy (IQR) 1900 (1800–2175)
with only four patients (15%) reporting them at the end of the
study. Pre-treatment, controlled, and uncontrolled seizures were
symptoms in 16% of the patients. By conclusion of the study, 12%
of the patients had controlled seizures on oral medications, and
no patients had uncontrolled seizures.
DISCUSSION
Our results show that frameless SRS is a safe and effective tech-
nique for the treatment of intracranial AVM. A large recent study
by Ding et al. reported an obliteration rate of 30% at 10 years,
and the present study with an obliteration rate of 58% at 3 years
compares favorably to these results (7). The higher rate of clo-
sure in the present study is may be due to generally smaller nidal
volumes, and generally lower grades, yet roughly equivalent mar-
ginal doses (7). It is worth noting that Spetzler–Martin grading
incorporates size into its calculation of grade (as well as draining
veins and eloquence of cortex), and therefore is unsurprisingly
correlated with obliteration rates. The results of this article with
regards to obliteration rates and dependent factors are consis-
tent with observations made in similar studies of radiosurgical
outcomes for treatment of intracranial AVM with Gamma Knife
FIGURE 2 | (A) Pre-radiosurgery, and (B) post-radiosurgery CT angios and
angiograms for a representative case with follow-up images taken at
2 years post-radiosurgery demonstrating complete nidal obliteration with no
residual draining vein.
(7–10). While other studies have shown a consistent and expected
dependence of AVM closure on dose, volume, grade, and follow-
up time, the present study only demonstrated a dependence on
follow-up time (8). This lack of dependence upon dose and vol-
ume may be attributable to a small sample size and the variance
within these factors, and therefore are negative results due to lack
of statistical power rather than truly negative results.
Our minimally invasive approach of obtaining CTA with or
without MRA for planning purposes prior to frameless SRS does
come with a notable drawback when treating AVM after emboliza-
tion with Onyx. Onyx, an ethylene vinyl alcohol polymer which
is solvated in dimethyl-sulfoxide (DMSO), is radio-opaque and
can cause artifact on CTA, which can make it difficult to properly
visualize the AVM nidus for treatment planning and follow-up.
The distribution of post-treatment neurological complications
in the present group compared similarly to reported series within
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Table 2 | Summary of AVM treatment characteristics and patient outcomes.
Variable Endpoint (p-Value)
Complete closure (n=15) Partial closure (n=6) Stable (n=5)
Median follow-up, months (IQR) 31 (24–39) 17 (11–22) 25 (18–29) 0.03
Spetzler martin grade – – – 0.26
I, n (%) 5 (33) 3 (50) 0 (0)
II, n (%) 8 (53) 3 (50) 2 (40)
III, n (%) 3 (20) 0 (0) 3 (60)
IV, n (%) 1 (6) 0 (0) 0 (0)
Median Nidus volume, cm3 (IQR) 1.15 (0.54–4.66) 3.42 (0.71–10.24) 4.42 (1.96–9.07) 0.63
Intervention 0.64
SRS only, n (%) 8 (53) 5 (83) 4 (80)
SRS+embolization or surgery, n (%) 7 (47) 1 (17) 1 (20)
Isodose, median % (IQR) 80 (76–85%) 77 (72–80%) 81 (80–81%) 0.24
Dose, median Gy (IQR) 1800 (1750–1950) 2050 (2000–2175) 2000 (2000–2200) 0.12
Table 3 | Summary of post-treatment adverse events and symptoms.
Variable Value
Post-treatment hemorrhage, n (%) 1 (4)
Post-treatment neurological symptoms
Headache, n (%) 4 (15)
Seizures, controlled/uncontrolled, n/n (%/%) 3/0 (12/0)
Motor deficits, n (%) 3 (12)
the Gamma Knife literature as well,with a significant improvement
occurring for major neurological symptoms including seizures and
motor function compared to pre-operative symptoms (9, 11). For
pre-treatment headaches, there was 66% rate of total resolution,
identical to the results of Steiner et al. (11).
Approximately, half of the patients in the present series experi-
enced pre-treatment hemorrhage. Pre-treatment hemorrhage can
vary greatly between studies in the literature, with some cohorts
consisting almost entirely of patients with hemorrhage, and others
entirely without (7, 11). Recent studies have shown that post-
radiosurgery hemorrhage can increase the time until AVM closure,
and previous work by Flickinger demonstrated that pre-treatment
hemorrhage can have a lasting impact on the resolution of neu-
rologic sequelae, although this last finding has been disputed
(7, 12, 13).
CONCLUSION
This small pilot series demonstrates that frameless SRS is a safe
and effective measure for treating intracranial AVM in utilizing
the traditional single fraction approach. Due to advanced imaging
and motion tracking technologies, it can achieve equivalent results
to traditional frame-based methods without the need for pins and
a stereotaxic frame. With further research, we may be able to max-
imize the benefits of this novel technology for the treatment of
intracranial AVM.
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